Citations 321
Faculty Opinions recommendation of Topoisomerase inhibitors and targeted delivery in cancer therapy.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of The essential kinase ATR: ensuring faithful duplication of a challenging genome.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available
Faculty Opinions recommendation of Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiect
Kaufmann, Scott H.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available